Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY

Next Previous
Trial Profile

STRIVE: A MULTICENTER PHASE 2, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE VS. BICALUTAMIDE IN MEN WITH PROSTATE CANCER WHO HAVE FAILED PRIMARY ANDROGEN DEPRIVATION THERAPY

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enzalutamide (Primary) ; Bicalutamide
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms STRIVE
  • Sponsors Medivation; Pfizer

    • Most Recent Events

    • 25 Aug 2021 Results of a meta-analysis assessing efficacy and safety of treatments for nonmetastatic castration-resistant prostate cancer using patient level data from two studies (IMAAGEN, STRIVE) and aggregate data from other eligible nmCRPC trials presented at the 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
    • 20 May 2021 Results of meta analysis of 6 trials including STRIVE and IMAAGEN presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 08 Apr 2021 Results of meta-analysis of 5 studies (ARN-509-001, PROSPER, STRIVE, ARAMIS, IMAAGEN & SPARTAN), published in the Journal of the National Cancer Institute.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top